Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 344 entries
View as:

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05476380 Org: User:
Start: 02/19/21 End: 12/01/24 Due: 12/01/25

External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD)

Phase: N/A Priority: Normal
NCT ID: NCT01634971 Org: User:
Start: 05/31/12 End: 12/31/16 Due: 12/31/17

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase: N/A Priority: Normal
NCT ID: NCT04907344 Org: User:
Start: 06/15/21 End: 06/30/25 Due: 06/30/26

Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06914050 Org: User:
Start: 04/30/25 End: 04/30/28 Due: 04/30/29

Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02605226 Org: User:
Start: 11/30/15 End: 12/31/18 Due: 12/31/19

Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05228743 Org: User:
Start: 09/01/20 End: 10/31/23 Due: 10/31/24

Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06496789 Org: User:
Start: 05/27/23 End: 12/31/24 Due: 12/31/25

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06487663 Org: User:
Start: 10/27/20 End: 10/27/26 Due: 10/27/27

Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04808687 Org: User:
Start: 03/31/21 End: 02/29/24 Due: 02/28/25

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

Phase: N/A Priority: Normal
NCT ID: NCT06495541 Org: User:
Start: 08/01/24 End: 07/30/28 Due: 07/30/29

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Phase: N/A Priority: Normal
NCT ID: NCT07031700 Org: User:
Start: 07/01/25 End: 07/30/27 Due: 07/30/28

Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04631757 Org: User:
Start: 12/15/20 End: 12/31/23 Due: 12/31/24

XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC

Phase: N/A Priority: Normal
NCT ID: NCT03389659 Org: User:
Start: 02/28/18 End: 06/30/22 Due: 06/30/23

Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02506361 Org: User:
Start: 05/31/15 End: 10/31/25 Due: 10/31/26

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05856864 Org: User:
Start: 06/01/24 End: 05/01/25 Due: 05/01/26

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

Phase: N/A Priority: Normal
NCT ID: NCT04553887 Org: User:
Start: 11/01/20 End: 05/01/23 Due: 05/01/24

Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT03874000 Org: User:
Start: 03/08/19 End: 06/05/22 Due: 06/05/23

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Phase: N/A Priority: Normal
NCT ID: NCT06375486 Org: User:
Start: 03/14/24 End: 06/15/26 Due: 06/15/27

Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06656559 Org: User:
Start: 10/31/24 End: 08/31/26 Due: 08/31/27

A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03708042 Org: User:
Start: 12/01/18 End: 12/01/23 Due: 12/01/24

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

Phase: N/A Priority: Normal
NCT ID: NCT04846634 Org: User:
Start: 08/31/21 End: 02/29/28 Due: 02/28/29

A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01758679 Org: User:
Start: 01/31/12 End: 12/31/16 Due: 12/31/17

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Phase: N/A Priority: Normal
NCT ID: NCT05507606 Org: User:
Start: 08/01/21 End: 08/01/24 Due: 08/01/25

Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01618474 Org: User:
Start: 05/31/12 End: 12/31/16 Due: 12/31/17

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Phase: N/A Priority: Normal
NCT ID: NCT06370065 Org: User:
Start: 04/27/23 End: 12/31/24 Due: 12/31/25